However, studies have indicated that selective inhibitor of PKCδ, Rottlerin, was toxic to cells after a certain concentration [23], so large-scale clinical trials will need to validate safety and prospective application of Rottlerin in DKD. Here, PRKCD is linked to diabetic kidney disease.